A DNA vaccine for the prevention of Ebola virus infection.
The NIH and Vical Inc are developing an intramuscular needle-free DNA vaccine containing plasmids encoding the envelope glycoprotein of Ebola virus (EBOV) from the Sudan and Zaire strains, and the nucleoprotein of EBOV Zaire strain. A phase I clinical trial demonstrated a good safety profile, with most adverse events limited to the site of injection and largely attributable to the delivery.
Dery
Markalain
M
Tulane University Health Sciences Center, Department of Medicine, Infectious Diseases Section, 1430 Tulane Ave SL-87, New Orleans, LA 70112-2699, USA. madery@tulane.edu
Bausch
Daniel G
DG
D002986:Clinical Trials as Topic; D000075202:Contraindications; D004353:Drug Evaluation, Preclinical; D046129:Ebola Vaccines / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D013329:Structure-Activity Relationship; D019444:Vaccines, DNA / Q000009:adverse effects / Q000276:immunology* / Q000493:pharmacokinetics
D046129:Ebola Vaccines; D019444:Vaccines, DNA